J I Hoare et al. 2022. Gynecol Oncol. 167(1):96-106. PMID: 35918200.
Product description:
Platinum-resistant HGSC cancer cells with a growth advantage in the presence of therapy that expand to create drug-resistant tumours.
Gender:
Female
CRISPR:
No
Production details:
Mice with OVCAR4 intraperitoneal xenografts initially responded to carboplatin but tumours eventually regrew indicating the in vivo development of carboplatin-resistance. Murine tumours were harvested at necropsy and dissociated to create IVR01.
Parental cell line:
OVCAR4-Luc cell lines
Model description:
Platinum-resistant HGSC in vivo cell line
Initial handling information:
Cells should be cultured without drug but used at low passage to ensure drug resistance is maintained
Growth medium:
DMEM containing 10% FBS and 1% penicillin/streptomycin. Cells should be cultured without drug but used at low passage to ensure drug resistance is maintained.
Temperature:
37° C
Mycoplasma free:
Yes
References:
H Hockings et al. 2022. Cancer Res. 85(18):3503-3517.PMID: 40299825
J I Hoare et al. 2022. Gynecol Oncol. 167(1):96-106. PMID: 35918200.
Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.
